Drug Trial Radar · NCT03052608
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
296
Actual
Start
Apr 27, 2017
Primary completion
Mar 20, 2020
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
LorlatinibDrug
ALK-positive NSCL treatment
CrizotinibDrug
ALK-positive NSCL treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) AssessmentTime frame: From time of Study Start up to 33 months
Locations
166 sites in 23 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Altamonte Springs, Florida
Florida Cancer Specialists
Brandon, Florida
Florida Cancer Specialists
Clearwater, Florida
Florida Cancer Specialists
Gainesville, Florida
Florida Cancer Specialists
Largo, Florida
Florida Cancer Specialists
Lecanto, Florida
Florida Cancer Specialists
Orange City, Florida
Florida Cancer Specialists
Orlando, Florida
Florida Cancer Specialists
Spring Hill, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Florida Cancer Specialists
Tampa, Florida
Florida Cancer Specialists
Tavares, Florida
Florida Cancer Specialists
The Villages, Florida
Florida Cancer Specialists
Winter Park, Florida
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Ophthalmic Consultants of Boston Inc
Boston, Massachusetts
The William P. Beetham Eye Institute, Joslin Diabetes Center
Boston, Massachusetts
University of Rochester Cancer Center Pharmacy
Rochester, New York
University of Rochester Medical Center
Rochester, New York
Tennessee Oncology, PLLC
Dickson, Tennessee
Tennessee Oncology, PLLC
Franklin, Tennessee
Tennessee Oncology, PLLC
Gallatin, Tennessee
Tennessee Oncology, PLLC
Hermitage, Tennessee
Tennessee Oncology, PLLC
Lebanon, Tennessee
Tennessee Oncology, PLLC
Murfreesboro, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
The Sarah Cannon Research Institute.
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Tennessee Oncology, PLLC
Shelbyville, Tennessee
Tennessee Oncology, PLLC
Smyrna, Tennessee
University of Washington Medical Center
Seattle, Washington
Centro Medico Austral
CABA, Argentina
Centro de Investigacion Pergamino SA
Pergamino, Buenos Aires, Argentina
Bendigo Day Surgery Collection Centre and Laboratory
Bendigo, Victoria, Australia
Bendigo Medical Imaging, Bendigo Hospital
Bendigo, Victoria, Australia
Melbourne Pathology
Bendigo, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.